Phenotypic and Functional Changes of Tumour Cells from Patients Treated with Monoclonal Anti-Idiotypic Antibodies
- 31 October 1990
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 32 (5) , 441-449
- https://doi.org/10.1111/j.1365-3083.1990.tb03184.x
Abstract
In this paper data are presented indicating that immunotherapy with monoclonal anti-idiotypic antibodies (MoAb anti-id) can provoke different responses in the B-cell tumour concerned. With respect to the course of disease during and after immunotherapy, the in vitro findings may very well explain the in vivo observations in the two patients (D.E.F., B.O.R.) with B-cell chronic lymphocytic leukaemia (B-CCL) who were treated with MoAb anti-id. After initial tumour reduction, there was a recurrence of tumour cells with altered functional and phenotypic properties. In both cases the recurring tumour cells still expressed the same idiotype. In one patient (D.E.F.) the phenotypic changes (a surface Ig change from IgM, IgG, IgA, and IgD to weakly positive IgM and IgD) and functional changes (a 10-fold increase in [3H]thymidine uptake and a decreased idiotype secretion in vitro), together with the in vivo findings with respect to the course of disease.sbd.at relapse an impressive tumour regrowth rate with constant serum idiotype level.sbd.suggest that immunoselection might have taken place favouring the survival and relapse of a less mature, more aggressive tumour cell population with a lower idiotype expression. In the second patient (B.O.R.), the phenotypic changes (an isotype change from IgM and IgD to IgM with the loss of IgD, and a gradual decrease in expression of CD19 and CD24) and functional changes (a 10-fold increase of idiotype secretion in vitro), together with the in vivo finding that the serum idiotype level had increased 25-fold compared with the preimmunotherapy serum level with comparable tumour load, strongly suggest an immunotherapy-induced differentiation of the malignant B cell. We also described an increased expression of CD74, detected by MoAb BoM22, on the recurring tumour cells of patient B.O.R., whereas the expression of HLA-DP, -DQ and -DR did not change. The significance of this finding is unclear.This publication has 30 references indexed in Scilit:
- The development of non-responsiveness to immunotherapy with monoclonal anti-idiotypic antibodies in a patient with B-CLLBritish Journal of Haematology, 1988
- Heterogeneous Responses of B-Cell Tumours to Anti-Ig and Anti-Idiotypic AntibodiesScandinavian Journal of Immunology, 1988
- Effect of tumor necrosis factor alpha on mitogen-activated human B cells.The Journal of Experimental Medicine, 1987
- Spontaneous Alteration of Idiotype in a Monoclonal B-Cell LymphomaNew England Journal of Medicine, 1985
- Emergence of Idiotype Variants during Treatment of B-Cell Lymphoma with Anti-Idiotype AntibodiesNew England Journal of Medicine, 1985
- HLA‐DC antigens can serve as recognition elements for human cytotoxic T lymphocytesEuropean Journal of Immunology, 1984
- Distinct HLA‐DR epitopes and distinct families of HLA‐DR molecules defined by 15 monoclonal antibodies (mAb) either anti‐DR or allo‐anti‐Iak crossreacting with human DR molecule. I. Cross‐inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent‐solubilized HLA molecules immobilized to a solid phase by a first mAbEuropean Journal of Immunology, 1983
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Membrane-Bound IgD on Human Lymphoid Cells, with Special Reference to Immunodeficiency and Immunoproliferative DiseasesImmunological Reviews, 1977
- In vitro tolerance induction of neonatal murine B cells.The Journal of Experimental Medicine, 1976